Oral transmucosal drug delivery system
This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.
1. A method of treating testosterone deficiency in a male subject in need thereof, the method comprising orally administering a compressed solid transmucosal dosage form comprising testosterone and a crystallization inhibition agent (CIA), wherein the CIA comprises:
I. a hydrophilic CIA selected from the group consisting of one or more polyethylene glycols (PEG) having a molecular weight ≥2000 which is solid at room temperature, polyvinylpyrrolidone (PVP), vinylpyrrolidone-vinyl acetate co-polymers, polyvinyl caprolactum-polyvinyl acetate-polyethylene glycol graft co-polymers, synthetic copolymers of ethylene oxide and propylene oxide, hydroxyl propyl cellulose, hydroxyl propyl methyl cellulose, polyethylene oxide, disaccharides, trioses, tetroses, sugar, trisaccharides, tetrasaccharides, oligosaccharides, polysaccharides, maltodextrin, polyols, or mixtures thereof;
II. a lipophilic CIA selected from the group consisting of oleic acid, a hydrogenated vegetable oil, cocoa butter, carnauba wax; beeswax; or mixtures thereof;
III. an amphiphilic CIA selected from the group consisting of polyethylene glycol glycerides, vitamin E-TPGS (d-alpha tocopherol polyethylene glycol 1000 succinate), mono-, di-, and tri-esters of sucrose with fatty acids, lecithin or mixtures thereof; or
IV. any combination of I-III;
wherein oral availability of the testosterone in the dosage form is higher compared with oral availability of a dosage form comprising testosterone and no CIA, wherein the dosage form does not adhere to a specific location in the buccal area of the subject and wherein the dosage form erodes in about 10 minutes to about 60 minutes.
2. The method of claim 1 , wherein the transmucosal permeability of the testosterone administered to the subject is improved compared with transmucosal permeability of a dosage form comprising testosterone and no CIA.
3. The method of claim 1 , wherein the transmucosal permeability is increased greater than 10% compared with the transmucosal permeability of a dosage form comprising testosterone and no CIA.
4. The method of claim 1 , wherein the transmucosal permeability is increased greater than 40% compared with the transmucosal permeability of a dosage form comprising testosterone and no CIA.
5. The method of claim 1 , wherein the method comprises an oral transmucosal dosage form comprising about 0.5 mg to about 10 mg testosterone.
6. The method of claim 1 , wherein the oral transmucosal dosage form erodes in about 10 minutes to about 30 minutes.
7. The method of claim 6 , wherein the oral transmucosal dosage form erodes in about 10 minutes to about 20 minutes.
8. The method of claim 1 , wherein the oral transmucosal dosage form erodes at a rate of about 5 mg/min to about 500 mg/min.
9. The method of claim 1 , wherein the oral transmucosal dosage form erodes at a rate of about 5 mg/min to about 150 mg/min.
10. The method of claim 1 , wherein the oral transmucosal dosage form does not disintegrate.
11. The method of claim 1 , wherein about 40% of the testosterone is released from the oral transmucosal dosage form within 5 minutes.
12. The method of claim 1 , wherein about 50% of the testosterone is released from the oral transmucosal dosage form within 15 minutes.
13. The method of claim 1 , wherein the method results in less irritation of gum tissue relative to a buccal bioadhesive tablet.
14. The method of claim 1 , wherein the oral transmucosal dosage form is administered 1 to 3 times per day.
15. The method of claim 1 , wherein the oral transmucosal dosage form is administered 3 times per day.
16. The method of claim 1 , wherein the oral transmucosal dosage form is a lozenge, lollipop, tablet or troche.
17. The method of claim 1 , wherein the subject is a hypogonadal man.
18. A method of treating testosterone deficiency in a male subject, comprising orally administering a compressed solid transmucosal dosage form comprising testosterone and a crystallization inhibition agent (CIA) to a subject at a dose of between about 0.5 mg and 20 mg testosterone per day, wherein the CIA comprises
I. a hydrophilic CIA selected from the group consisting of one or more polyethylene glycols (PEG) having a molecular weight ≥2000 which is solid at room temperature, polyvinylpyrrolidone (PVP), vinylpyrrolidone-vinyl acetate co-polymers, polyvinyl caprolactum-polyvinyl acetate-polyethylene glycol graft co-polymers, synthetic copolymers of ethylene oxide and propylene oxide, hydroxyl propyl cellulose, hydroxyl propyl methyl cellulose, polyethylene oxide, disaccharides, trioses, tetroses, sugar, trisaccharides, tetrasaccharides, oligosaccharides, polysaccharides, maltodextrin, polyols, or mixtures thereof;
II. a lipophilic CIA selected from the group consisting of oleic acid, a hydrogenated vegetable oil, cocoa butter, carnauba wax; beeswax; or mixtures thereof;
III. an amphiphilic CIA selected from the group consisting of polyethylene glycol glycerides, vitamin E-TPGS (d-alpha tocopherol polyethylene glycol 1000 succinate), mono-, di-, and tri-esters of sucrose with fatty acids, lecithin or mixtures thereof; or
IV. any combination of I-III;
wherein the dosage form does not adhere to a specific location in a buccal area of the subject and wherein the dosage form erodes in about 10 minutes to about 60 minutes.
19. The method of claim 18 , wherein about 0.5 mg to about 10 mg testosterone is administered per dose.
20. The method of claim 18 , wherein the oral transmucosal dosage form is administered 1 to 3 times per day.
21. A method of administering testosterone to a male subject, the method comprising orally administering a compressed solid transmucosal dosage form comprising testosterone and a crystallization inhibition agent (CIA) orally to a subject, wherein the oral transmucosal dosage form is administered 1 to 3 times per day and provides reduced fluctuations in plasma testosterone levels, wherein the dosage form does not adhere to a specific location in the buccal area of the subject, and wherein the CIA comprises
I. a hydrophilic CIA selected from the group consisting of one or more polyethylene glycols (PEG) having a molecular weight ≥2000 which is solid at room temperature, polyvinylpyrrolidone (PVP), vinylpyrrolidone-vinyl acetate co-polymers, polyvinyl caprolactum-polyvinyl acetate-polyethylene glycol graft co-polymers, synthetic copolymers of ethylene oxide and propylene oxide, hydroxyl propyl cellulose, hydroxyl propyl methyl cellulose, polyethylene oxide, disaccharides, trioses, tetroses, sugar, trisaccharides, tetrasaccharides, oligosaccharides, polysaccharides, maltodextrin, polyols, or mixtures thereof;
II. a lipophilic CIA selected from the group consisting of oleic acid, a hydrogenated vegetable oil, cocoa butter, carnauba wax; beeswax; or mixtures thereof;
III. an amphiphilic CIA selected from the group consisting of polyethylene glycol glycerides, vitamin E-TPGS (d-alpha tocopherol polyethylene glycol 1000 succinate), mono-, di-, and tri-esters of sucrose with fatty acids, lecithin or mixtures thereof; or
IV. any combination of I-III
wherein the dosage form erodes in about 10 minutes to about 60 minutes.